Cite
HARVARD Citation
Ahearn, A. et al. (2022). A Programmatic Response, Including Bamlanivimab or Casirivimab-imdevimab Administration, Reduces Hospitalization and Death in COVID-19 Positive Abdominal Transplant Recipients. Transplantation. 106 (2), p. . [Online].